IMMUNOVANT, INC. Business Combination, Acquisition Related Costs
IMMUNOVANT, INC. (IMVT) reported Business Combination, Acquisition Related Costs of $2.80 million for the 9-month period ending 2020-12-31, per its 10-Q filed 2021-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2021-06-01
- IMMUNOVANT, INC. business combination, acquisition related costs for the quarter ending 2020-12-31 was $0.00.
- IMMUNOVANT, INC. business combination, acquisition related costs for the quarter ending 2020-09-30 was $0.00.
- IMMUNOVANT, INC. business combination, acquisition related costs for the quarter ending 2020-06-30 was $2.80M.
- IMMUNOVANT, INC. business combination, acquisition related costs for the quarter ending 2020-03-31 was $0.00.
- IMMUNOVANT, INC. business combination, acquisition related costs for fiscal 2020 was $2.80M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | $0.00 derived: sum of 2 quarters · filed 2021-02-16 | $2.80M 10-Q · filed 2021-02-16 | $2.80M derived: sum of 4 quarters · filed 2021-06-01 |
| 2020-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | $2.80M 10-Q · filed 2020-11-12 | $2.80M derived: sum of 3 quarters · filed 2021-06-01 | |
| 2020-06-30 | $2.80M 10-Q · filed 2020-08-12 | $2.80M derived: sum of 2 quarters · filed 2021-06-01 | ||
| 2020-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | $2.80M 10-K · filed 2021-06-01 | ||
| 2019-12-31 | $2.80M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |